Vinpocetine’s immunomodulating, anti-oxidant, anti-inflammatory, ant-ifibrotic, and PDE inhibiting potencies ameliorate bleomycin-induced pulmonary fibrosis

  • سال انتشار: 1402
  • محل انتشار: مجله علوم پایه پزشکی ایران، دوره: 26، شماره: 1
  • کد COI اختصاصی: JR_IJBMS-26-1_003
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 176
دانلود فایل این مقاله

نویسندگان

Mohamed Balaha

Clinical Pharmacy Department, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia

Abdullah Alahmari

Clinical Pharmacy Department, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia

Samah Kandeel

Histology Department, Faculty of Medicine, Tanta University, El-Gish Street, Postal No. ۳۱۵۲۷ Tanta, Egypt

Marwa Balaha

Department of Pharmacy, University G. d’Annunzio, Chieti-Pescara, Italy

چکیده

Objective(s): Pulmonary fibrosis (PF) is a global health problem with a high economic burden. Intratracheal administration of bleomycin is the best model that resembles the pathogenesis of PF in humans. Recently, vinpocetine proved to have neuroprotective, cardioprotective, hepatoprotective, anti-aging, and antifibrotic effects through its anti-oxidant, immunomodulating, and anti-inflammatory activities. The present study investigated the antifibrotic potentiality of vinpocetine in a rat model of PF induced by intratracheal bleomycin administration. Materials and Methods: PF induced by a single intratracheal instillation of ۵ mg/kg bleomycin in nine-week-old Wister rats. Oral vinpocetine was used at doses of ۵, ۱۰, or ۲۰ mg/kg to treat PF for ۲۱ days immediately after the bleomycin instillation. Results: Vinpocetine dose-dependently ameliorates PF induced by bleomycin administration since vinpocetine effectively restored the normal body weight gain rates, pulmonary architecture, and collagen fiber distribution and suppressed the elevated BALF cell count, lymphocytes and neutrophils percentage, BALF, IL-۶, TNF-α, and TGF-β۱ levels and LDH activity, lung tissue MDA level, PDE activity, hydroxyproline content, immunohistochemical expression of α-SMA and CD۶۸ positive macrophage, and fibrosis score. Meanwhile, it efficiently augmented the reduced BALF macrophage percentage, IL-۱۰ level, lung tissue GSH level, CAT, and SOD activities. Conclusion: Vinpocetine may propose a new promising agent to manage PF.

کلیدواژه ها

Antifibrotic, Anti-inflammatory, Anti-oxidant, Pulmonary Fibrosis, PDE, Vinpocetine

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.